Premium
Persistent aplasia after chemotherapy for acute myeloid leukaemia treated with stem cell transplantation from a matched unrelated donor after dose‐reduced conditioning
Author(s) -
Hambach Lothar,
Heil Gerhard,
Hertenstein Bernd,
Ganser Arnold
Publication year - 2002
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2002.03742.x
Subject(s) - myeloid leukaemia , medicine , aplasia , chemotherapy , transplantation , stem cell , conditioning , oncology , myeloid , autologous stem cell transplantation , biology , genetics , statistics , mathematics
Summary. Persistent aplasia is a rare complication with poor prognosis after intensive chemotherapy for acute leukaemia. A 59‐year‐old man with acute myeloid leukaemia (AML), was treated after 186 d of chemotherapy‐induced persistent aplasia with an allogeneic peripheral blood stem cell transplantation (PBSCT) from a matched unrelated donor (MUD) after dose‐reduced conditioning. The patient remains in complete haematological remission more than 8·5 months after haematological recovery. We believe that this is the first reported case of treatment for chemotherapy‐induced persistent aplasia with MUD‐PBSCT after dose‐reduced conditioning, a procedure that can be successfully performed even in elderly patients.